Dyne Therapeutics, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. The filing was signed May 2, 2022. Dyne is a pre-revenue biotechnology company developing muscle-disease therapeutics using its FORCE platform.
Financial performance and position
- Revenue: None; the company reported no revenue and has no products for sale. Profitability and revenue margins are therefore not meaningful.
- Expenses and loss: R&D expense was $28.2 million, up $9.6 million (about 52%) year over year; G&A was $7.5 million, up $1.0 million (about 16%). Total operating expenses were $35.8 million, up $10.6 million (about 42%). Net loss was $35.6 million versus $25.0 million; basic and diluted loss per share was $0.69 versus $0.50.
- Cash flow: Operating activities used $50.7 million, compared with $18.4 million in Q1 2021. Investing activities used $2.1 million; financing provided less than $0.1 million. Cash, cash equivalents and restricted cash declined $52.9 million during the quarter.
- Liquidity: Cash and cash equivalents were $148.0 million and marketable securities were $175.2 million at March 31, totaling $323.2 million. Management estimated these resources would fund operating expenses and capital needs into the second half of 2024, subject to assumptions and business-plan changes.
- Debt and liabilities: Total liabilities were $51.3 million, including $32.8 million of current and noncurrent lease liabilities. The balance sheet reports no borrowing balance; the filing describes historical borrowings under a bank loan agreement but does not provide a clear current debt balance in the presented text.
- Equity: Stockholders’ equity was $336.5 million; accumulated deficit was $264.1 million. The company had 51.65 million common shares outstanding as of April 30, 2022.
Material changes versus Q1 2021
Operating losses and cash used in operations increased as the company expanded research and development and advanced manufacturing and IND-enabling work. R&D cost increases included personnel, external manufacturing and research, and facility-related expenses. Q1 2021 financing included $157.2 million of net proceeds from a follow-on offering; Q1 2022 had no comparable offering proceeds. Marketable-securities unrealized losses contributed to comprehensive loss in Q1 2022.
Outlook, risks and contingencies
- Management expected to submit regulatory filings for DYNE-101 in Q2 2022 and, subject to regulatory clearance, begin dosing in a global multiple-ascending-dose trial in mid-2022.
- The FDA placed the DYNE-251 IND on clinical hold and requested additional clinical and nonclinical information. Dyne expected to respond in Q2 2022 and planned a mid-2022 trial start only if the FDA found the response satisfactory.
- Dyne anticipated submitting an IND for DYNE-301 in the second half of 2022. These were forward-looking plans, not achieved milestones; the filing states that its candidates were in preclinical development and that none had entered clinical trials.
- The company expects significant ongoing losses and increasing expenses, and will need substantial additional funding. Potential equity or debt financing could dilute shareholders or impose restrictive terms; collaborations or licenses could require surrendering valuable rights. A $400 million shelf registration and a $150 million at-the-market program were available, but no ATM sales had been made as of the filing.
- Key risks include clinical and regulatory uncertainty—especially the DYNE-251 hold—preclinical results not predicting human outcomes, dependence on third-party and single-source manufacturers, competition, intellectual-property and licensing exposure, and potential COVID-19 effects on studies, supply chains and operations. Dyne reported no material pandemic-related business disruption to date.
- The company had an 8.5-year office and laboratory lease; base rent was scheduled to begin in April 2022 at $0.4 million per month, increasing to as much as $0.5 million during the lease term.
Important facts for investors to verify
- Subsequent regulatory updates and actual trial-start status for DYNE-101, DYNE-251 and DYNE-301, including whether the DYNE-251 clinical hold was lifted.
- Current cash, marketable securities, operating cash burn and whether the projected runway into the second half of 2024 remains achievable.
- Availability and potential use of the shelf and ATM financing programs, and the resulting dilution or financing terms.
- Current manufacturing supply capacity and any developments affecting the company’s third-party or single-source suppliers.